Food and Drug Administration officials reportedly raised conflict-of-interest concerns while a new panel was being assembled to review several injectable peptides. The issue centered on whether people with links to peptide-related businesses should be appointed to help evaluate the products.
The panel is expected to consider whether Americans should get wider access to seven injectable peptides that had previously been restricted. Those limits were tied to potential safety concerns, making the makeup of the review group especially significant.
According to the report, the concerns emerged during the Trump administration as the government put together the panel. That suggests internal debate not only over the peptides themselves, but also over who should take part in decisions that could influence access to them.
The development adds another layer to an already sensitive review process. With the FDA weighing broader availability of products that have faced scrutiny before, questions about panel independence and possible industry ties are likely to remain part of the discussion.
